会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明授权
    • Method and an apparatus for executing simulation for system performance evaluation
    • 用于执行系统性能评估仿真的方法和装置
    • US08249850B2
    • 2012-08-21
    • US12393155
    • 2009-02-26
    • Tomoki KatoNoriyasu NakayamaHiroyuki Hieda
    • Tomoki KatoNoriyasu NakayamaHiroyuki Hieda
    • G06F17/50
    • G06F17/5009
    • The present invention relates to a technique for executing performance evaluation simulation of a system to be implemented by software or hardware. A simulation apparatus includes a first acquisition section for executing existing tentative software to acquire a first execution log, a division section for dividing the first execution log into a plurality of basic processing units, a basic processing execution log production section for modifying some of the plural basic processing units to produce a basic processing execution log to be used for simulation, and a simulation execution section for inputting the basic processing execution log to a hardware model to execute the simulation to acquire information required for the performance evaluation.
    • 本发明涉及一种用于执行由软件或硬件实现的系统的性能评估仿真的技术。 模拟装置包括用于执行现有的暂时软件以获取第一执行日志的第一获取部分,用于将第一执行日志分成多个基本处理单元的分割部分,用于修改多个基本处理单元中的一些的基本处理执行日志生成部分 用于生成用于模拟的基本处理执行日志的基本处理单元,以及用于将基本处理执行日志输入到硬件模型以执行模拟以获取执行评估所需的信息的模拟执行部。
    • 9. 发明申请
    • Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity
    • 具有5-Ht4受体激活活性的喹诺酮羧酸化合物
    • US20080255113A1
    • 2008-10-16
    • US10595948
    • 2004-11-10
    • Tomoki KatoKiyoshi KawamuraMikio MoritaChikara Uchida
    • Tomoki KatoKiyoshi KawamuraMikio MoritaChikara Uchida
    • A61K31/5377C07D405/14A61K31/4709C07D401/12C07D401/14C07D413/14
    • C04B35/632C07D401/12C07D401/14C07D405/14
    • This invention provides a compound of the formula (I): wherein Het represents a heterocyclic group having one nitrogen atom, to which B binds directly, and from 4 to 7 carbon atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 4 substituents independently selected from the group consisting of substituents α1; A represents an alkylene group having from 1 to 4 carbon atoms; B represents a covalent bond or an alkylene group having from 1 to 5 carbon atoms; R1 represents an isopropyl group, a n-propyl group or a cyclopentyl group; R2 represents a methyl group, a fluorine atom or a chlorine atom; R3 independently represents (i) an oxo group, a hydroxy group, an amino group, an alkylamino group or a carboxyl group; (ii) a cycloalkyl group having from 3 to 8 carbon atoms, and said cycloalkyl group being substituted by 1 to 5 substituents, or (iii) a heterocyclic group having from 3 to 8 atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 5 substituents, and n is 1, 2 or 3, or a pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.
    • 本发明提供式(I)化合物:其中Het表示具有一个氮原子的杂环基团,B直接与该碳原子结合,并且具有4至7个碳原子,所述杂环基团未被取代或被1至4个取代基取代 独立地选自取代基α1, A表示具有1至4个碳原子的亚烷基; B表示共价键或具有1至5个碳原子的亚烷基; R 1表示异丙基,正丙基或环戊基; R 2表示甲基,氟原子或氯原子; R 3独立地表示(i)氧代基,羟基,氨基,烷基氨基或羧基; (ii)具有3至8个碳原子的环烷基,所述环烷基被1至5个取代基取代,或(iii)具有3至8个原子的杂环基,所述杂环基未被取代或被1 至5个取代基,n为1,2或3,或其药学上可接受的盐。 这些化合物具有5-HT 4受体激动活性,因此可用于治疗哺乳动物,特别是人类的胃食管反流病,非溃疡性消化不良,功能性消化不良,肠易激综合征等。